Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Soci

- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS® gene editing therapiesDURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic...

Related Keywords

Washington ,United States ,Mei Burris ,Precision Biosciences Inc ,University Of Pennsylvania Gene Therapy Program ,Dtil Biosciences Inc ,American Society Of Gene Cell Therapy ,Waltere Washington Convention Center ,Nasdaq ,Precision Biosciences ,American Society ,Cell Therapy ,Convention Center ,Eliminate Hepatitisb Virus In Vivo ,Gene Editing ,Complex Diseases ,Sustained Transduction ,Infant Macaque ,Presidential Symposium ,Top Abstracts ,Hydroxyacid Oxidase ,Primary Hyperoxaluria Type ,Poster Board Number ,Gene Targeting ,Gene Correction ,Gene Therapy Program ,Investor Relations ,